Related Experiment Videos
MIH: epidemiologic clinic study in paediatric patient
1Department of Clinical Science and Traslational Medicine University of Rome "Tor Vergata"
ORAL & Implantology
|January 4, 2013
Summary
Molar Incisor Hypomineralization (MIH) affects 7.3% of children, primarily impacting first molars. Early diagnosis and tailored treatments are crucial for managing this common enamel defect in pediatric patients.
Area of Science:
- Pediatric Dentistry
- Dental Public Health
- Developmental Biology
Background:
- Molar Incisor Hypomineralization (MIH) is a defect of enamel quality and quantity.
- It commonly affects first permanent molars and may involve incisors.
- MIH prevalence and distribution require further investigation in diverse populations.
Purpose of the Study:
- To evaluate the incidence and prevalence of MIH in a pediatric population.
- To analyze the distribution patterns of MIH among dental elements.
- To explore potential correlations of MIH with existing literature data.
Main Methods:
- Random sample of 1500 pediatric patients aged 0-14 years.
- Data collected from the Pediatric Dentistry department of Policlinico Tor Vergata, Rome (1996-2011).
- Analysis of MIH occurrence, affected teeth, and patient demographics.
Main Results:
- MIH identified in 110 patients (7.3%), aged 4-15 years (average age 9.7).
- First permanent molars were most frequently affected (39.8% of hypoplastic defects).
- Molars were involved in 56% of MIH cases, incisors in 44%; equal prevalence in males and females.
Conclusions:
- MIH is a frequent condition in the pediatric population.
- Early and differential diagnosis is essential for effective management.
- Therapeutic protocols, including preventive and restorative treatments, aim to restore function and aesthetics.
Related Concept Videos
01:26Introduction to Epidemiology
Epidemiology, known as the cornerstone of public health, involves studying the distribution and determinants of health-related events in defined populations and applying these insights to control health issues. This is essential for understanding how diseases spread, identifying populations at greater risk, and implementing measures to control or prevent outbreaks. Epidemiology addresses not only infectious diseases but also non-communicable conditions like cancer and cardiovascular disease,...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Investigation of Disease Outbreaks
Multistate foodborne outbreaks pose significant public health risks and require meticulous investigation to identify sources and implement control measures. The Centers for Disease Control and Prevention (CDC) utilizes a dynamic seven-step process for these investigations, integrating data from laboratories, interviews, and environmental assessments to protect public health.Outbreak Detection: The detection of multistate outbreaks typically begins with PulseNet, the CDC's national laboratory...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...